FIELD: biotechnology.
SUBSTANCE: invention relates to modified fibroblast growth factor 1 (FGF-1) polypeptides, and can be used in medicine for the treatment or prevention of a corneal disease, disorder or condition in a mammal, including herpetic keratopathy, neurotrophic keratopathy, corneal endothelial dystrophy or damage caused by a chemical or blister. The following is proposed: a recombinant modified FGF-1 polypeptide containing mutations in the wild-type FGF-1 sequence, namely the polypeptide contains three substitutions Cys16Ser, Ala66Cys and Cys117Val and methionine attached to the N-terminus of the following SEQ ID NO: 1.
EFFECT: invention provides the production of an FGF-1 polypeptide with an increased ability to induce cell proliferation compared to wild-type FGF-1 presented in the following SEQ ID NO: 1.
13 cl, 12 dwg, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
| TREATMENT OF ABNORMAL VISCERAL FAT DEPOSITION WITH FIBROBLAST GROWTH FACTOR 3 (sFGFR3) SOLUBLE POLYPEPTIDES | 2018 |
|
RU2794170C2 |
| FUSED SERPINE POLYPEPTIDES AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2746550C2 |
| COMBINED COMPOSITION CONTAINING FGF-18 COMPOUND | 2016 |
|
RU2745453C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| SUBUNIT VACCINE FOR TREATING OR PREVENTING RESPIRATORY TRACT INFECTION | 2020 |
|
RU2811991C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
